Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 4
2005 1
2006 4
2007 2
2008 3
2010 4
2011 6
2012 6
2013 6
2014 9
2015 5
2016 5
2017 8
2018 2
2019 7
2020 3
2021 5
2022 7
2023 3
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

85 results

Results by year

Filters applied: . Clear all
Page 1
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma.
Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, Phillips E, Sangha R, Schlag R, Seymour JF, Townsend W, Trněný M, Wenger M, Fingerle-Rowson G, Rufibach K, Moore T, Herold M, Hiddemann W. Marcus R, et al. Among authors: wenger m. N Engl J Med. 2017 Oct 5;377(14):1331-1344. doi: 10.1056/NEJMoa1614598. N Engl J Med. 2017. PMID: 28976863 Free article. Clinical Trial.
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.
Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer KA, Stilgenbauer S, Döhner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M, Hallek M. Goede V, et al. Among authors: wenger m. N Engl J Med. 2014 Mar 20;370(12):1101-10. doi: 10.1056/NEJMoa1313984. Epub 2014 Jan 8. N Engl J Med. 2014. PMID: 24401022 Free article. Clinical Trial.
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS).
Morschhauser F, Flinn IW, Advani R, Sehn LH, Diefenbach C, Kolibaba K, Press OW, Salles G, Tilly H, Chen AI, Assouline S, Cheson BD, Dreyling M, Hagenbeek A, Zinzani PL, Jones S, Cheng J, Lu D, Penuel E, Hirata J, Wenger M, Chu YW, Sharman J. Morschhauser F, et al. Among authors: wenger m. Lancet Haematol. 2019 May;6(5):e254-e265. doi: 10.1016/S2352-3026(19)30026-2. Epub 2019 Mar 29. Lancet Haematol. 2019. PMID: 30935953 Clinical Trial.
Perceptual learning produces perceptual objects.
Wenger MJ, Rhoten SE. Wenger MJ, et al. J Exp Psychol Learn Mem Cogn. 2020 Mar;46(3):455-475. doi: 10.1037/xlm0000735. Epub 2019 Jun 20. J Exp Psychol Learn Mem Cogn. 2020. PMID: 31219302 Free PMC article.
Endocrine and Local IGF-I in the Bony Fish Immune System.
Franz AC, Faass O, Köllner B, Shved N, Link K, Casanova A, Wenger M, D'Cotta H, Baroiller JF, Ullrich O, Reinecke M, Eppler E. Franz AC, et al. Among authors: wenger m. Biology (Basel). 2016 Jan 26;5(1):9. doi: 10.3390/biology5010009. Biology (Basel). 2016. PMID: 26821056 Free PMC article. Review.
Follicular Lymphoma Treated with First-Line Immunochemotherapy: A Review of PET/CT in Patients Who Did Not Achieve a Complete Metabolic Response in the GALLIUM Study.
Barrington SF, Mir F, El-Galaly TC, Knapp A, Nielsen TG, Sahin D, Wenger M, Kostakoglu L, Trotman J, Meignan M. Barrington SF, et al. Among authors: wenger m. J Nucl Med. 2022 Aug;63(8):1149-1154. doi: 10.2967/jnumed.121.262869. Epub 2021 Dec 2. J Nucl Med. 2022. PMID: 34857656 Free PMC article. Review.
Estimated Ages of JUUL Twitter Followers.
Kim AE, Chew R, Wenger M, Cress M, Bukowski T, Farrelly M, Hair E. Kim AE, et al. Among authors: wenger m. JAMA Pediatr. 2019 Jul 1;173(7):690-692. doi: 10.1001/jamapediatrics.2019.0922. JAMA Pediatr. 2019. PMID: 31107511 Free PMC article.
85 results